Two Sigma Securities’s PharmaCyte Biotech PMCB Stock Holding History

Two Sigma Securities’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,360	Closed	-$10.9K	–	2217
2026 Q1	$10.9K	Sell	16,360 -8,193	-33%	-$6.27K	﹤0.01%	1458
2025 Q4	$17.8K	Buy	+24,553	New	+$22.1K	﹤0.01%	1198
2024 Q3	–	Sell	-27,750	Closed	-$54.4K	–	3464
2024 Q2	$54.4K	Buy	+27,750	New	+$59.8K	﹤0.01%	2565

Other funds holding PMCB

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Two Sigma Securities's PMCB Position: Q2 2026 in Review

Two Sigma Securities sold out of PharmaCyte Biotech (PMCB) in Q2 2026, closing a stake of 16,360 shares — an estimated $10.9K sold.

Two Sigma Securities first reported a position in PMCB in Q2 2024 and held it in 3 quarters. The position peaked at $54.4K in Q2 2024. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

Two Sigma Securities reported no remaining PharmaCyte Biotech position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 16,360 PharmaCyte Biotech shares in Q2 2026, an estimated $10.9K.
Two Sigma Securities first reported a position in PharmaCyte Biotech in Q2 2024 and held it in 3 quarters.
Two Sigma Securities's PharmaCyte Biotech position peaked at $54.4K in Q2 2024.
28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.